Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1312 clinical trials
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).

  • 0 views
  • 20 Jul, 2022
  • 24 locations
Evaluation of GLR2007 for Advanced Solid Tumors

This study is designed to determine the safety, tolerability, and optimal dosing of GLR2007 in participants with advanced solid tumors that do not respond well to standard clinical therapies.

kidney function test
cancer treatment
ct scan
contrast-enhanced magnetic resonance imaging
BRAF
  • 0 views
  • 16 Feb, 2024
  • 4 locations
IPG7236 in Patients With Advanced Solid Tumors

This is a Phase 1, Multi-center, Non-randomized, Open-label, Dose-escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of IPG7236 Administered Orally as a Single Agent in Patients with Advanced Solid Tumors. The study will include a dose escalation phase (Part 1) and a dose …

  • 0 views
  • 03 Dec, 2021
  • 1 location
IPG7236 in Patients With Advanced Solid Tumors  

This is a Phase 1, Multi-center, Non-randomized, Open-label, Dose-escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of IPG7236 Administered Orally as a Single Agent in Patients with Advanced Solid Tumors. The study will include a dose escalation phase (Part 1) and a dose …

  • 0 views
  • 14 Mar, 2022
  • 1 location
NBE-002 in Patients With Advanced Solid Tumors

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.

anthracycline
solid tumour
carcinoma
anthracyclines
cancer
  • 0 views
  • 05 Aug, 2020
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Eligibility Adults age 18 and older with pancreatic cancer, breast cancer, or a solid tumor that has not been cured by standard therapies. Also, children age 12-17 with a solid tumor (other than a muscle tumor) with no standard therapy options.

x-rays
ct scan
renal function test
blood transfusion
platelet count
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of SGN-B6A in Advanced Solid Tumors

It will also study whether SGN-B6A works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-B6A should be given to participants. Part B will use the dose found in Part A to find out how safe SGN-B6A is …

cancer, ovarian
ovarian ca
cancer of the ovary
solid tumour
ovarian cancer
  • 0 views
  • 05 Aug, 2020
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs (KYANITE-1)

Monotherapy KB707 dose escalation and expansion cohorts enrolled adults with advanced solid tumor malignancies affecting the lungs who had progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy.

  • 0 views
  • 12 Dec, 2025
A Study of SY 5609 a Selective CDK7 Inhibitor in Advanced Solid Tumors

This is a dose escalation study and will be the first to administer SY-5609 alone to humans with select advanced solid tumors and in combination with Fulvestrant to patients with HR positive, HER2-negative breast cancer.

gonadotropin
HER2
solid tumour
her2/neu-negative breast cancer
alopecia
  • 0 views
  • 16 Feb, 2024
  • 5 locations
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of BPI-1178 in subjects with advanced solid tumor, as well as the subjects with advanced hormone receptor-positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer.

aptt
HER2
thromboplastin
immunostimulant
solid tumour
  • 0 views
  • 16 Feb, 2024
  • 1 location